Genprex
(NASDAQ: GNPX), a clinical-stage gene therapy company developing
potentially life-changing technologies for patients with cancer and diabetes,
today announced the appointment of three new members to its Board of Directors.
The new appointments, which include Brent Longnecker, CEO of Longnecker &
Associates, Jose A. Moreno Toscano, CEO of LFB USA Inc, and William R. (“Will”)
Wilson, Jr., chairman, president and CEO of Wilson Land & Cattle Co., are
designed to strengthen Genprex as it executes on its key clinical programs,
continues to build its pipeline, and evaluates future license or corporate
partnership agreements. “We are honored to have Brent, Jose and Will join our
Board in what we believe is a transformational time for our Company,” Genprex
CEO Rodney Varner said in the news release. “Their combined experience in
regulatory compliance, business development, clinical trial management, and
deal structuring will be invaluable as we continue to develop gene therapy drug
candidates and pursue partnerships for our drug candidates. The addition of
these outstanding directors, together with our new senior executive hires and a
significantly strengthened balance sheet, puts us in an excellent position to
execute our plans.”
To view the full press release, visit http://ibn.fm/1KWZc
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing treatments for cancer and other serious
diseases. Genprex’s technologies are designed to administer disease-fighting
genes to provide new treatment options for large patient populations with
cancer and other serious diseases who currently have limited treatment options.
Genprex works with world-class institutions and collaborators to in-license and
develop drug candidates to further its pipeline of gene therapies in order to
provide novel treatment approaches for patients with cancer and other serious
diseases. The company’s lead product candidate, Oncoprex(TM) immunogene therapy
for non-small cell lung cancer (“NSCLC”), uses the company’s unique,
proprietary platform which delivers cancer-fighting genes by encapsulating them
into nanoscale hollow spheres called nanovesicles, which are then administered
intravenously and taken up by tumor cells where they express proteins that are
missing or found in low quantities. In January 2020, the FDA granted Fast Track
Designation for Oncoprex in combination with AstraZeneca’s Tagrisso(R) for the
treatment of NSCLC. For more information, please visit the company’s website
at www.Genprex.com
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
